{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:21:38Z","timestamp":1761895298729,"version":"build-2065373602"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.rpsm.2011.04.005","type":"journal-article","created":{"date-parts":[[2011,7,5]],"date-time":"2011-07-05T09:56:33Z","timestamp":1309859793000},"page":"169-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Terapia electroconvulsiva como tratamiento del s\u00edndrome neurol\u00e9ptico maligno"],"prefix":"10.1016","volume":"4","author":[{"given":"Ernesto Jos\u00e9","family":"Verdura Vizca\u00edno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ballesteros Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Sanz-Fuentenebro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsm.2011.04.005_bib0005","first-page":"79","article-title":"The neuroleptic malignant syndrome","volume":"41","author":"Caroff","year":"1980","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.143.11.1374","article-title":"Lethal catatonia","volume":"143","author":"Mann","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-3223(95)00552-8","article-title":"Neuroleptic malignant syndrome and catatonia: one entity or two?","volume":"39","author":"Fink","year":"1996","journal-title":"Biol Psychiatry"},{"year":"2003","series-title":"Catatonia: A Clinician's Guide to Diagnosis and Treatment","author":"Fink","key":"10.1016\/j.rpsm.2011.04.005_bib0020"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/070674370905400704","article-title":"Catatonia: A syndrome appears, disappears, and is rediscovered","volume":"547","author":"Fink","year":"2009","journal-title":"Can J Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.rpsm.2011.04.005_bib0030","first-page":"S54","article-title":"Severe and uncommon involuntary movement disorders due to psychotropic drugs","volume":"37","author":"Stubner","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0035","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome","volume":"164","author":"Strawn","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1176\/appi.ajp.2009.09050703","article-title":"ECT in the treatment of a patient with catatonia: Consent and complications","volume":"167","author":"Zisselman","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/bja\/85.1.129","article-title":"Neuroleptic malignant syndrome","volume":"85","author":"Adnet","year":"2000","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/jnp.2007.19.4.477","article-title":"Possible neuroleptic malignant syndrome associated with paliperidone","volume":"19","author":"Duggal","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0055","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1055\/s-2003-40681","article-title":"Life threatening neuroleptic malignant syndrome due to olanzapine","volume":"30","author":"Kopf","year":"2003","journal-title":"Psychiatr Prax"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0060","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4103\/0019-5359.35807","article-title":"Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine","volume":"61","author":"Mishra","year":"2007","journal-title":"Indian J Med Sci"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0065","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1176\/appi.ajp.2008.07121972","article-title":"Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine","volume":"165","author":"Marshall","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0070","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200923060-00003","article-title":"Neuroleptic malignant syndrome associated with atypical antipsychotic drugs","volume":"23","author":"Trollor","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0075","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.1989.01810100056011","article-title":"Risk factors for neuroleptic malignant syndrome","volume":"46","author":"Keck","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0140-6736(91)90138-F","article-title":"Serum iron and neuroleptic malignant syndrome","volume":"338","author":"Rosebush","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0006-3223(98)00109-7","article-title":"Serum iron in catatonia and neuroleptic malignant syndrome","volume":"44","author":"Lee","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0090","series-title":"Neuroleptic Malignant Syndrome and Related Conditions","first-page":"1","article-title":"Neuroleptic malignant syndrome","author":"Caroff","year":"2003"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0095","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1176\/appi.ajp.158.10.1714","article-title":"Association of the TaqI A polymorphism of the dopamine D2 receptor gene with predisposition to neuroleptic malignant syndrome","volume":"158","author":"Suzuki","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/ajp.156.2.169","article-title":"Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome","volume":"156","author":"Gurrera","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0105","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1176\/ajp.138.8.1115","article-title":"Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome: a case report","volume":"138","author":"Feibel","year":"1981","journal-title":"Am J Psychiatry"},{"year":"2000","series-title":"Diagnostic and Statistical Manual of Mental Disorders","key":"10.1016\/j.rpsm.2011.04.005_bib0110"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0115","first-page":"25","article-title":"Neuroleptic malignant syndrome","volume":"24","author":"Caroff","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0120","first-page":"23","article-title":"Medical aspects of catatonia","volume":"16","author":"Levenson","year":"2009","journal-title":"Prim Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0125","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1176\/appi.ajp.160.7.1233","article-title":"Catatonia in psychiatric classification: a home of its own","volume":"160","author":"Taylor","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0130","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1176\/ps.49.9.1163","article-title":"Neuroleptic malignant syndrome: a review","volume":"49","author":"Pelonero","year":"1998","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0135","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00004583-199211000-00028","article-title":"Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome","volume":"31","author":"Woodbury","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3928\/0048-5713-20000501-10","article-title":"Treatment of neuroleptic malignant syndrome","volume":"30","author":"Davis","year":"2000","journal-title":"Psychiatr Ann"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0145","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1017\/S1092852900013407","article-title":"Is lorazepam a treatment for neuroleptic malignant syndrome?","volume":"5","author":"Francis","year":"2000","journal-title":"CNS Spectr"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0150","first-page":"381","article-title":"Drug treatment of the neuroleptic malignant syndrome","volume":"27","author":"Sakkas","year":"1991","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0155","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/archinte.1989.00390090009002","article-title":"Neuroleptic malignant syndrome: review of response to therapy","volume":"149","author":"Rosenberg","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0160","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1176\/ajp.2006.163.8.1450","article-title":"Subcutaneous Apomorphine for neuroleptic malignant syndrome","volume":"163","author":"lattanzi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0165","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/cc5148","article-title":"Managing an effective treatment for neuroleptic malignant syndrome","volume":"11","author":"Reulbach","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/jnp.18.1.131","article-title":"Use of intravenous valproate in a patient with neuroleptic malignant syndrome","volume":"18","author":"Tadke","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1010389215197","article-title":"Clinical management of neuroleptic malignant syndrome. New York Presbyterian Hospital, Westchester Division, USA","volume":"72","author":"Susman","year":"2001","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0180","series-title":"The ECT Handbook","first-page":"47","article-title":"The use of ECT in neuropsychiatric disorders","author":"Trimble","year":"2005"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1600-0447.1987.tb02782.x","article-title":"A successful electroconvulsive treatment of neuroleptic malignant syndrome","volume":"75","author":"Hermesh","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0190","first-page":"267","article-title":"Treatment choice in neuroleptic malignant syndrome","volume":"8","author":"Scheftner","year":"1992","journal-title":"Convuls Ther"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0195","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/j.1440-1614.1999.00630.x","article-title":"Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases","volume":"33","author":"Trollor","year":"1999","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0200","first-page":"49","article-title":"Electroconvulsive therapy in drug resistant neuroleptic malignant syndrome","volume":"56","author":"Patel","year":"2008","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0205","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1600-0447.1987.tb02927.x","article-title":"Role of electroconvulsive therapy in neuroleptic malignant syndrome","volume":"76","author":"Adityanjee","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0210","series-title":"The ECT Handbook","first-page":"30","article-title":"The use of ECT in the treatment of schizophrenia and catatonia","author":"Fear","year":"2005"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0215","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/0006-3223(87)90010-2","article-title":"Neuroleptic malignant syndrome: Review and analysis of 115 cases","volume":"22","author":"Addonizio","year":"1987","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.yct.0000159325.08303.45","article-title":"Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome","volume":"21","author":"Ozer","year":"2005","journal-title":"J ECT"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0225","unstructured":"Reid IC. How does ECT work? En: Scott AIF I, editor. The ECT Handbook. 2nd ed. Glasgow: Bell and Bain Limited; 2005. p. 201-203."},{"year":"2002","series-title":"Electroconvulsive Therapy","author":"Abrams","key":"10.1016\/j.rpsm.2011.04.005_bib0230"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0235","series-title":"The ECT Handbook","first-page":"170","article-title":"Adverse effects of ECT","author":"Benbow","year":"2005"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0240","first-page":"99","article-title":"Seizure threshold and ECT. Importance for good clinical practice of ECT","volume":"29","author":"Poulet","year":"2003","journal-title":"Encephale"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0245","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/01.yct.0000244242.10167.fd","article-title":"Open trial on the efficacy of right unilateral electroconvulsive therapy with titration and high charge","volume":"22","author":"Rosa","year":"2006","journal-title":"J ECT"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0250","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/YCT.0b013e31816fe9ba","article-title":"To reestimulate or not in dose titration","volume":"24","author":"Scott","year":"2008","journal-title":"J ECT"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0255","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0165-0327(99)00169-X","article-title":"A prospective follow-up study of ECT outcome in older depressed patients","volume":"60","author":"Brodaty","year":"2000","journal-title":"J Affect Disord"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0260","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1176\/ajp.150.6.904","article-title":"Cardiovascular complications of ECT in depressed patients with cardiac disease","volume":"150","author":"Zielinski","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0265","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00000542-198707000-00004","article-title":"Malignant hyperthermia susceptibility in neuroleptic malignant syndrome","volume":"67","author":"Caroff","year":"1987","journal-title":"Anaesthesiology"},{"year":"2001","series-title":"The practice of electroconvulsive therapy: recommendations for treatment. American Psychiatric Association. Committee on Electroconvulsive Therapy","author":"Weiner","key":"10.1016\/j.rpsm.2011.04.005_bib0270"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0275","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1136\/bmj.288.6434.1878","article-title":"Rhabdomyolysis and malignant hyperpyrexia","volume":"28","author":"Denborough","year":"1984","journal-title":"British Medical Journal"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0280","first-page":"221","article-title":"Caffeine contracture in neuroleptic malignant syndrome [abstract]","volume":"9","author":"Araki","year":"1988","journal-title":"Muscle and Nerve"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0285","first-page":"266","article-title":"A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia","volume":"1","author":"Tollefson","year":"1982","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0290","first-page":"9","article-title":"Neuroleptic malignant syndrome and malignant hyperthermia","volume":"145","author":"Grigg","year":"1988","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0295","first-page":"35","article-title":"Cardiovascular effects of ECT","volume":"5","author":"Welch","year":"1989","journal-title":"Convuls Ther"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0300","first-page":"50","article-title":"Neuroleptic malignant syndrome and ECT","volume":"49","author":"Vallance","year":"1993","journal-title":"Br J Hosp Med"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0305","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1272\/jnms.66.262","article-title":"Repeated propofol anesthesia for a patient with a history of neuroleptic malignant syndrome","volume":"66","author":"Sakamoto","year":"1999","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0310","first-page":"645","article-title":"Pathophysiology and therapy of malignant neuroleptic syndrome","volume":"63","author":"Weller","year":"1992","journal-title":"Nervenarzt"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0315","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/BF03011418","article-title":"Malignant hyperthermia","volume":"32","author":"Brit","year":"1985","journal-title":"Can Anaestb Soc"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0320","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ajp.145.9.1175a","article-title":"Neuroleptic malignant syndrome and malignant hypertherrnia","volume":"145","author":"Grigg","year":"1988","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0325","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0034-9356(10)70171-7","article-title":"Sugammadex, a novel drug for neuromuscular blockade reversal","volume":"57","author":"Fern\u00e1ndez Mer\u00e9","year":"2010","journal-title":"Rev Esp Anestesiol Reanim"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0330","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00124509-199912000-00011","article-title":"Multiple ECT for neuroleptic malignant syndrome","volume":"15","author":"Ray","year":"1999","journal-title":"J ECT"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0335","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1192\/bjp.bp.109.066183","article-title":"Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial","volume":"196","author":"Kellner","year":"2010","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0340","first-page":"138","article-title":"The \u201chalf-age\u201d stimulation strategy for ECT dosing","volume":"12","author":"Petrides","year":"1996","journal-title":"Convuls Ther"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0345","first-page":"269","article-title":"Multiple ECT late in the course of neuroleptic malignant syndrome","volume":"13","author":"McKinney","year":"1997","journal-title":"Convulsive Therapy"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0355","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00005053-198605000-00001","article-title":"Conventional and multiple-monitored electroconvulsive therapy. A comparison in major depressive episodes","volume":"174","author":"Maletzky","year":"1986","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.rpsm.2011.04.005_bib0360","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0033-3182(10)70709-X","article-title":"Neuroleptic malignant syndrome: Further lessons from a case report","volume":"51","author":"Casamassima","year":"2010","journal-title":"Psychosomatics"}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989111000760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989111000760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:25:44Z","timestamp":1761823544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989111000760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1888989111000760"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2011.04.005","relation":{},"ISSN":["1888-9891"],"issn-type":[{"type":"print","value":"1888-9891"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Terapia electroconvulsiva como tratamiento del s\u00edndrome neurol\u00e9ptico maligno","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2011.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 SEP y SEPB. Published by Elsevier Espa\u00f1a S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}